- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03529825
Rifaximin for Infection Prophylaxis in Hematopoietic Stem Cell Transplantation
Study Overview
Detailed Description
This study is for patients who will be having a blood/marrow transplant (BMT) to treat leukemia, lymphoma or other cancer of the blood. The blood or marrow cells will come from another person (donor)-allogeneic BMT. Bacterial infections and acute graft versus host disease (AGVHD) are frequent complications of allogeneic BMT. Bacterial infections sometimes happen because injury to the gut during transplant allows gut bacteria to cross the injured gut barrier and get to the blood. AGVHD happens when certain white blood cells, called T-cells, in the donor cells (the graft) attack the patient's body.
Primary purpose of the study is to see if rifaximin can improve the balance of bacteria within the gut, which has been shown to improve transplant outcomes. It will also assess whether rifaximin can reduce the risk of infection in blood/marrow transplant (BMT).
Study Type
Enrollment (Actual)
Phase
- Early Phase 1
Contacts and Locations
Study Locations
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Children's Healthcare of Atlanta
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Allogeneic HSCT recipients between the ages of 2 and 21 years.
- Underlying hematologic malignancy, regardless of donor type or graft source.
- Myeloablative conditioning regimen.
Exclusion Criteria:
- Known hypersensitivity to rifaximin, or other rifamycin antimicrobial agents.
- Minimally toxic conditioning regimen (e.g. low dose TBI based). Since these regimens induce minimal myelosuppression and gut injury, patients receiving them probably stand little to gain from antibiotic prophylaxis.
- Patients with ongoing bacterial, viral or fungal active infections are not eligible for this study. Patients who remain on broad spectrum antibiotics for the treatment of a previous infection are not eligible.
- The use of prophylactic antibiotics is not permitted.
- Following the standard practice in blood and marrow transplantation, pregnant or breast feeding patients will be excluded
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Rifaximin
Rifaximin will be administered twice a day orally or by nasogastric tube to patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT).
|
Rifaximin will be administered twice a day orally or by nasogastric tube, at a dose of 15 mg/kg divided BID with a maximum dose of 1,650 mg, day -7 to day +28 or discharge (maximum duration 36 days).
|
No Intervention: Retrospective comparison cohort
Thirty six patients who underwent HSCT for hematologic malignancies, and received myeloablative conditioning, without prophylactic antibiotics, between 2013-2017 enrolled in the Aflac biorepository will comprise the comparison arm.
Clinical data on transplant and infection characteristics is available and linked to stool microbiome samples already analyzed and described.
Stored plasma and peripheral blood mononuclear cells are available for further analysis.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Alterations to microbiome diversity in children treated with rifaximin compared to the historical cohort.
Time Frame: Period between the start of the preparative regimen and day 28 post transplant
|
Composition will be assessed using 16S RNA sequencing.
The Shannon index will be calculated for quantification of bacterial diversity.
|
Period between the start of the preparative regimen and day 28 post transplant
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rates of BSI pathogen infection/colonization frequency during the treatment period compared to the historical cohort.
Time Frame: Period between the start of the preparative regimen and day 28 post transplant
|
Results of the GI pathogen panel, a test incorporated into routine patient care detecting DNA or RNA of 22 common viral, bacterial, and parasitic organisms, will provide a second assessment through molecular detection of the presence of common organisms associated with intestinal dysbiosis.
|
Period between the start of the preparative regimen and day 28 post transplant
|
Transplant related mortality (TRM)
Time Frame: Period between the start of the preparative regimen and day 28 post transplant
|
Number of deaths occurring in continuous complete remission.
|
Period between the start of the preparative regimen and day 28 post transplant
|
Number of patients with Acute GVHD
Time Frame: Period between the start of the preparative regimen and day 100 post transplant
|
Early onset (before day 100) acute GVHD (including all grades, and stratified by grades) will be assessed according to the Blood and Marrow Transplant Clinical Trials Network Manual version 2, 2005, section 1 using the NIH consensus criteria
|
Period between the start of the preparative regimen and day 100 post transplant
|
Number of patients with Chronic GVHD including overlap syndrome
Time Frame: Period between the start of the preparative regimen and year 5 post-transplant.
|
Chronic GVHD including overlap syndrome, will be assessed according to the 2014 NIH consensus criteria.
|
Period between the start of the preparative regimen and year 5 post-transplant.
|
Number of patients with other Infections
Time Frame: Period between the start of the preparative regimen and day 28 post transplant
|
Other Infections will be defined in accordance with the Blood and Marrow Transplant Clinical Trials Network Manual of Procedures
|
Period between the start of the preparative regimen and day 28 post transplant
|
Number of patients with relapse free survival at 1 year
Time Frame: Period between the start of the preparative regimen and year 1 post-transplant.
|
Survival without relapse of underlying malignancy.
|
Period between the start of the preparative regimen and year 1 post-transplant.
|
Overall number of patients survived at 1 year
Time Frame: Period between the start of the preparative regimen and year 1 post-transplant.
|
Survival with or without relapse of underlying malignancy.
|
Period between the start of the preparative regimen and year 1 post-transplant.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Muna Qayed, MD MSc, Emory University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB00101158
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Microbial Colonization
-
Karolinska InstitutetCompletedMicrobial Colonization and Colorectal Disease
-
NHS FifeUniversity of TurkuUnknownDental Caries | Oral Microbial ColonizationUnited Kingdom
-
University Magna GraeciaRecruiting
-
BLIS Technologies LimitedRecruiting
-
Min-Tze LIONGInternational Islamic University MalaysiaRecruiting
-
VU University of AmsterdamWageningen University and Research; Maag Lever Darm Stichting; Cidrani; WholeFiber and other collaboratorsActive, not recruiting
-
BLIS Technologies LimitedActive, not recruiting
-
Becton, Dickinson and CompanyCompleted
-
Washington University School of MedicineCompletedMicrobial ColonizationUnited States
-
Cairo UniversityUnknown
Clinical Trials on Rifaximin
-
Bausch Health Americas, Inc.CompletedIrritable Bowel Syndrome With DiarrheaUnited States, United Kingdom, Germany
-
Bausch Health Americas, Inc.CompletedSickle Cell DiseaseUnited States, Canada, Kenya
-
Bausch Health Americas, Inc.CompletedLiver CirrhosisUnited States, Russian Federation
-
Alfasigma S.p.A.TerminatedDiverticulitisFrance, Germany, Italy, Netherlands, Spain, United Kingdom
-
Bausch Health Americas, Inc.CompletedOvert Hepatic EncephalopathyUnited States
-
SandozTerminatedTravelers' DiarrheaMexico
-
Sun Yat-sen UniversityRecruitingHepatic Encephalopathy | Hepatitis B | HBV | Effect of Drug | Liver Failure, Acute on Chronic | RifaximinChina
-
National University Hospital, SingaporeNational University, SingaporeCompletedIrritable Bowel Syndrome With DiarrheaSingapore
-
Shanghai Changzheng HospitalUnknown
-
Bausch Health Americas, Inc.Active, not recruitingHepatic EncephalopathyUnited States, Australia, Canada, Puerto Rico